Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for trea ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

Objective responses included: 2 PRs among 3 MSI-H patients with both responders having pancreatic ductal adenocarcinoma. One patient with MSI-H PDAC was initially misclassified as MSI-H small bowel ...

IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...

Novel IGSF8 Plus Keytruda Evaluated in Phase 1 Trial for Solid Tumors ... for the treatment of patients with KRAS-mutant pancreatic cancer. A treatment combination of avutometinib and defactinib is ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

“Keytruda and Welireg are approved therapies that have led to improved outcomes for some cancer patients ... hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate ...

liver cancer, pancreatic cancer and ovarian cancer. While there are inherent clinical and regulatory risks, the positive track record of TTFs in trials may support future expansions in cancer ...

Cabozantinib is the active ingredient in two of Exelixis' three approved drugs (Cabometyx and Cometriq) and its strongest US patent covering cabozantinib’s composition of matter expires in 2030.

Your vote at this year’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled for December 17, 2024, is ...

The drugmaker emphasized plans to move further away from singular reliance on Keytruda while reporting solid sales growth in ...